Posted by Michael Wonder on 02 Feb 2026
Donanemab in early Alzheimer's disease: important questions remain unanswered
30 January 2026 - For the treatment of Alzheimer's disease, it is crucial to distinguish between those with mild cognitive impairment without dementia and those with mild Alzheimer's dementia. However, this distinction is not made in the presented study.
For the treatment of Alzheimer's disease, it is crucial to distinguish between those with mild cognitive impairment without dementia and those with mild Alzheimer's dementia. However, this distinction is not made in the presented study.
